Medix Biochemica Ab Oy

10/15/2026 | Press release | Distributed by Public on 10/15/2026 00:41

MEDICA 16-19 November, 2026


Meet Medix Biochemica at MEDICA 2026: Building the Future of Diagnostics

Join Medix Biochemica at MEDICA 2026 in Düsseldorf, Germany! Visit us in Hall 3, Booth F41, where we will be showcasing our expanded portfolio of Recombinant Products and high-performance raw materials designed specifically for IVD (in vitro diagnostics) manufacturers worldwide.

Backed by a recent $5 million investment in state-of-the-art recombinant antigen manufacturing and technology upgrades, Medix Biochemica provides scalable, highly consistent, and sustainable alternatives to traditional serum- and tissue-derived diagnostic reagents.

Event Details at a Glance

Dates: 16 - 19 November, 2026

Place: Messe Düsseldorf. Düsseldorf, Germany

Location: Hall 3, Booth F41

Book a meeting with our team beforehand to make the most of your time at the exhibition and discuss your recombinant and diagnostic strategy.

Meet our Team at MEDICA

Kevin Martin
Sr. Global Corporate Account Director
Alex Leyshon
Senior Director of Sales
Dominic Hussey
Global Corporate Account Manager
Brooke Knaust
Director, Product Management
Maiju Palokangas
Director, Product Management
Maria Voutilainen
Global Product Manager
Dal Dhillon
Commercial Manager
Michael Heimann
Sales Manager
Etienne Thibault
Sales Representative
Emmi Keränen
Inside Sales Representative
Gargee Kashyap
Global Marketing Manager

Why talk to us at MEDICA?

IVD manufacturers face increasing supply chain pressures regarding native biological materials, including sourcing constraints, lot-to-lot variability, and tightening regulatory restrictions on animal-derived inputs.

Whether you are already evaluating recombinant materials or considering a future transition from native antigens, our team can discuss your application, technical requirements and long-term supply needs.

Data Spotlight: Recombinant TSH Commutability

Our recombinant portfolio already performs alongside native material. In a commutability study, recombinant and native TSH (product 610175) were spiked into buffer and into three donor samples at six concentrations (n=18). Each sample was measured on the Abbott Architect and Beckman DxI platforms.

  • Comparable to native: recombinant and native TSH performed comparably on both analyzers.

  • Linear across the clinical range: both showed excellent linearity across the clinical measuring range.

  • Minimal matrix effects: recovery in donor samples was high relative to buffer.

TSH Commutability in Donor Samples: Architect vs. DxI Platform Comparison and Recombinant Spike Recovery


Not attending Medica?

You can still experience our high-quality raw materials and explore our recombinant program firsthand. We offer complimentary samples and evaluation kits for qualifying IVD partners to support and accelerate your assay development.

Medix Biochemica Ab Oy published this content on October 15, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 15, 2026 at 06:41 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]